English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/17739
Compartir / Impacto:
Estadísticas
Add this article to your Mendeley library MendeleyBASE
Citado 0 veces en Web of Knowledge®  |  Pub MebCentral Ver citas en PubMed Central  |  Ver citas en Google académico
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Título

Pomegranate juice supplementation in chronic obstructive pulmonary disease: a 5-week randomized, double-blind, placebo-controlled trial

AutorCerdá, Begoña; Soto, C.; Albaladejo, M. D.; Martínez, P.; Sánchez-Gascón, F.; Tomás Barberán, Francisco; Espín de Gea, Juan Carlos
Palabras claveAntioxidant
Ellagitannin
Ellagic acid
Oxidative stress
Bioavailability
Microflora
Fecha de publicación2006
EditorNature Publishing Group
CitaciónEuropean Journal of Clinical Nutrition 60(2): 245-253 (2006)
Resumen[Objective]: The aim of the present study is to investigate the effect of antioxidant polyphenol-rich pomegranate juice (PJ) supplementation for 5 weeks on patients with stable chronic obstructive pulmonary disease (COPD), since the oxidative stress plays a major role in the evolution and pathophysiology of COPD.
[Design]: A randomized, double-blind, placebo-controlled trial was conducted.
[Subjects]: A total of 30 patients with stable COPD were randomly distributed in two groups (15 patients each).
[Interventions]: Both groups consumed either 400 ml PJ daily or matched placebo (synthetic orange-flavoured drink) for 5 weeks. Trolox Equivalent Antioxidant Capacity (TEAC) of PJ, blood parameters (14 haematological and 18 serobiochemical), respiratory function variables, bioavailability of PJ polyphenols (plasma and urine) and urinary isoprostane (8-iso-PGF2) were evaluated.
[Results]: The daily dose of PJ (containing 2.66 g polyphenols) provided 4 mmol/l TEAC. None of the polyphenols present in PJ were detected in plasma or in urine of volunteers. The most abundant PJ polyphenols, ellagitannins, were metabolized by the colonic microflora of COPD patients to yield two major metabolites in both plasma and urine (dibenzopyranone derivatives) with no TEAC. No differences were found (P>0.05) between PJ and placebo groups for any of the parameters evaluated (serobiochemical and haematological), urinary 8-iso-PGF2, respiratory function variables and clinical symptoms of COPD patients.
[Conclusions]: Our results suggest that PJ supplementation adds no benefit to the current standard therapy in patients with stable COPD. The high TEAC of PJ cannot be extrapolated in vivo probably due to the metabolism of its polyphenols by the colonic microflora. The understanding of the different bioavailability of dietary polyphenols is critical before claiming any antioxidant-related health benefit.
Descripción9 pages, 3 tables, 1 figure.-- Published online 9 November 2005.
Versión del editorhttp://dx.doi.org/10.1038/sj.ejcn.1602309
URIhttp://hdl.handle.net/10261/17739
DOI10.1038/sj.ejcn.1602309
ISSN0954-3007 (Print)
1476-5640 (Online)
Aparece en las colecciones: (CEBAS) Artículos
Ficheros en este ítem:
No hay ficheros asociados a este ítem.
Mostrar el registro completo
 



NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.